A recent study of 843 patients from three hospitals that compared the assessment of HER2 status using FDA-approved immunohistochemistry and fluorescence in situ hybridization assays versus a quantitative reverse transcription PCR (qRT-PCR) assay by Oncotype DX®, showed a high false negative rate for the qRT-PCR assay.
This is a preview of subscription content, log in via an institution to check access.
References
Ignatiadis, M., Desmedt, C., Sotiriou, C., de Azambuja, E. & Piccart, M. HER-2 as a target for breast cancer therapy. Clin. Cancer Res. 15, 1848–1852 (2009).
Paik, S. et al. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. J. Natl Cancer Inst. 94, 852–854 (2002).
Wolff, A. C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118–145 (2007).
Sauter, G., Lee, J., Bartlett, J. M., Slamon, D. J. & Press, M. F. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27, 1323–1333 (2009).
Dabbs, D. J. et al. High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study. J. Clin. Oncol. 32, 4279–4285 (2011).
Baehner, F. L. et al. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J. Clin. Oncol. 28, 4300–4306 (2010).
Noske, A. et al. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res. Treat. 126, 109–117 (2011).
Lehmann-Che, J. et al. Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches. Br. J. Cancer 104, 1739–1746 (2011).
Sotiriou, C. & Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790–800 (2009).
Oncotype DX® Breast Cancer Assay Quantitative single gene scores. Oncotype DX®Breast Cancer Assayhttp://www.oncotypedx.com/en-US/Breast/HealthcareProfessional/QuanitativeScores.aspx (2011).
Acknowledgements
Michail Ignatiadis and Christos Sotiriou have received grants from Breast Cancer Research Foundation (BCRF), “Fonds de la recherché scientifique” FNRS, and MEDIC foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C. Sotiriou is co-inventor of the Gene Expression Grade Index and owner of patents WO 2006/119593 and WO 2009/056366. M. Ignatiadis declares no competing interests.
Rights and permissions
About this article
Cite this article
Ignatiadis, M., Sotiriou, C. Should we assess HER2 status by Oncotype DX®?. Nat Rev Clin Oncol 9, 12–14 (2012). https://doi.org/10.1038/nrclinonc.2011.188
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.188
- Springer Nature Limited
This article is cited by
-
A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2
Modern Pathology (2017)
-
Gene expression-based prognostic and predictive tools in breast cancer
Breast Cancer (2015)
-
Patient profiling in breast cancer—is knowledge power?
Nature Reviews Clinical Oncology (2012)
-
Perspectives on Systems Biology Applications in Diabetic Kidney Disease
Journal of Cardiovascular Translational Research (2012)